Incyte Corporation
NASDAQ:INCYBiotechnology
-$0.77 today
- Market cap
- $24.01B
- Beta
- 0.79
- P/E (TTM)
- 13.7
- EPS (TTM)
- $7.18
Volume 1.21M
Average 1.58M
INCY Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Incyte CorporationNASDAQ: INCY
Retained Earnings · Q2 FY2026 · quarter ended Jun 2026
Retained earnings turns positive
Q2 FY2026 retained earnings was $1.1B, compared with -$509.68M a year earlier.
Context
- Retained earnings amounted to 14.0% of total assets at the end of Q2 FY2026, up 5.3 pp from a year earlier.
- Retained earnings increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps rising in the next quarterly balance sheet after a +316.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- 213.77M USD
- Year-over-year change
- +119.9%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 213.77M | +119.9% |
| FY2024 | 2024-12-31 | (1.07B) | -768.9% |
| FY2023 | 2023-12-31 | 160.39M | +136.7% |
| FY2022 | 2022-12-31 | (437.21M) | +43.8% |
| FY2021 | 2021-12-31 | (777.87M) | — |
Retained Earnings vs competitors
How INCY compares with its peers on the latest reported figures
- INCY's Jun 2026 retained earnings of $1.1B is the 3rd highest of the 11 companies compared; the peer median is -$375.53M.
- Its year-over-year change of +316.4% is the highest of 11, against a peer median of -6.7%.
- Retained earnings amounts to 14.0% of total assets for INCY, versus a peer median of 102.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $37.62B | +11.7% | +15.4% | 90.2% | |
| Jun 2026 | $4.42B | +22.9% | -34.9% | 35.3% | |
| Jun 2026 | $1.1B | +316.4% | — | 14.0% | |
| Jun 2026 | $583.25M | +26.4% | +10.5% | 26.7% | |
| Jul 2026 | -$262.53M | -19.6% | — | 10.5% | |
| Sep 2026 | -$303.09M | -13.4% | — | 214.8% | |
| Mar 2026 | -$447.96M | -48.0% | — | 128.2% | |
| Aug 2026 | -$630.13M | +31.9% | — | 52.7% | |
| Mar 2026 | -$637.78M | -53.0% | — | 158.3% | |
| Mar 2026 | -$1.2B | -19.2% | — | 527.5% | |
| Sep 2026 | -$1.93B | -0.0% | — | 114.7% | |
| Peer median (excluding INCY) | -$375.53M | -6.7% | +10.5% | 102.4% | |
Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.06B | 2.95B | 3.21B | 1.69B | 3.1B |
| Short-term Investments | 290.75M | 287.54M | 442.67M | 470.26M | 482.79M |
| Net Receivables | 616.3M | 644.88M | 743.56M | 853.15M | 1.02B |
| Inventory | 27.9M | 42M | 62.97M | 58.87M | 101.06M |
| Other Current Assets | 126.28M | 167.01M | 182.83M | 168.91M | 317.83M |
| Total Current Assets | 3.12B | 4.09B | 4.65B | 3.24B | 5.02B |
| Property, Plant & Equipment (Net) | 751.47M | 765.61M | 777.05M | 794.21M | 758.41M |
| Goodwill | 155.59M | 155.59M | 155.59M | 155.59M | 133M |
| Intangible Assets | 150.76M | 129.22M | 123.55M | 113.8M | 117.13M |
| Long-term Investments | 221.27M | 133.68M | 187.72M | 18.81M | 47.99M |
| Tax Assets | 467.54M | 457.94M | 631.89M | 762.07M | 515.29M |
| Other Non-current Assets | 68.06M | 106.1M | 260.92M | 360.8M | (47.99M) |
| Total Non-current Assets | 1.81B | 1.75B | 2.14B | 2.21B | 1.52B |
| Total Assets | 4.93B | 5.84B | 6.78B | 5.44B | 6.96B |
| Account Payables | 172.11M | 277.55M | 109.6M | 197.47M | 209.94M |
| Short-term Debt | 0 | 0 | 0 | 0 | 10.21M |
| Tax Payables | 0 | 7.11M | 42.3M | 23.78M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 328.26M | 435.86M | 545.01M | 724.83M | 1.07B |
| Total Current Liabilities | 854.31M | 1.16B | 1.24B | 1.64B | 1.52B |
| Long-term Debt | 0 | 0 | 0 | 0 | 14.51M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 12.88M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 277.41M | 283.71M | 322.73M | 321.31M | 216.11M |
| Total Non-current Liabilities | 309.04M | 313.79M | 351.89M | 354.85M | 288.2M |
| Total Liabilities | 1.16B | 1.47B | 1.59B | 2B | 1.8B |
| Common Stock | 221K | 223K | 224K | 193K | 198K |
| Retained Earnings | (777.87M) | (437.21M) | 160.39M | (1.07B) | 213.77M |
| Accumulated OCI | (19.45M) | 15.07M | 13.11M | (13.12M) | 25.46M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 3.77B | 4.37B | 5.19B | 3.45B | 5.17B |
| Total Debt | 44.82M | 41.46M | 38.29M | 43.54M | 69.43M |
| Net Debt | (2.01B) | (2.91B) | (3.18B) | (1.64B) | (3.03B) |
Incyte Corporation
NASDAQ:INCY
Intrinsic Alpha fair value
Locked
Current Price
$117.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.